Related Experiment Video

Updated: Apr 25, 2026

Following in Real Time the Impact of Pneumococcal Virulence Factors in an Acute Mouse Pneumonia Model Using Bioluminescent Bacteria
11:32

Following in Real Time the Impact of Pneumococcal Virulence Factors in an Acute Mouse Pneumonia Model Using Bioluminescent Bacteria

Published on: February 23, 2014

14.6K

Wandering pneumonia caused by dabigatran

Masakazu Kono1, Kousuke Hirota, Ayako Yokoe

  • 1Department of Pulmonary Medicine, Tokyo Rosai Hospital, Japan.

Internal Medicine (Tokyo, Japan)
|August 19, 2014
PubMed

Insights

A 74-year-old man developed lung consolidation after taking dabigatran (a novel oral anticoagulant). The condition resolved after stopping the medication, suggesting a potential drug-induced lung injury.

Area of Science:

  • Pulmonology
  • Pharmacology
  • Internal Medicine

Background:

  • Novel oral anticoagulants (NOACs) like dabigatran are increasingly used.
  • Pulmonary complications associated with dabigatran are rare.
  • Previous reports of dabigatran-induced lung injury include alveolar hemorrhage and eosinophilic pneumonia.

Observation:

  • A 74-year-old male presented with pulmonary consolidation and chest pain post-dabigatran administration.
  • The lung consolidation exhibited spontaneous resolution and migration to another lung area, termed 'wandering pneumonia'.
  • Transbronchial lung biopsy did not reveal specific interstitial lung disease.

Findings:

  • A spontaneous disappearance of lung opacity occurred after discontinuing dabigatran.
  • No recurrence of the pulmonary consolidation was observed.
  • This case suggests a potential link between dabigatran and an unusual presentation of drug-induced lung injury.

Implications:

  • Clinicians should consider drug-induced lung injury in patients presenting with unexplained pulmonary findings, even with novel medications.
  • The spectrum of dabigatran-induced pulmonary toxicity may be broader than previously recognized.
  • Further investigation into the potential for various pulmonary injuries from novel drugs is warranted.

More Related Videos

Pseudomonas aeruginosa Induced Lung Injury Model07:24

Pseudomonas aeruginosa Induced Lung Injury Model

Published on: October 29, 2014

18.1K
A Mouse Model for the Transition of Streptococcus pneumoniae from Colonizer to Pathogen upon Viral Co-Infection Recapitulates Age-Exacerbated Illness12:21

A Mouse Model for the Transition of Streptococcus pneumoniae from Colonizer to Pathogen upon Viral Co-Infection Recapitulates Age-Exacerbated Illness

Published on: September 28, 2022

3.9K

Related Concept Videos

Pneumonia I: Introduction01:29

Pneumonia I: Introduction

Pneumonia is an infection of the lower respiratory tract that leads to inflammation of the lung parenchyma, often resulting in the accumulation of inflammatory exudate in the alveoli and airways. Unlike the watery, low-protein fluid exudate in pulmonary edema, the exudate in this case is a thick fluid rich in immune cells, proteins, and debris produced during infection and inflammation.This impairs gas exchange and can lead to consolidation of lung tissue. The infection may be caused by a...
20
Pneumonia I: Introduction01:30

Pneumonia I: Introduction

Pneumonia is an acute respiratory infection that targets the lungs, specifically the alveoli. These tiny air sacs, essential for oxygen exchange, become engorged with pus and fluid, severely hindering breathing, decreasing oxygen absorption, and causing significant pain and discomfort during respiration.
Risk Factors
Various factors influence the likelihood of developing pneumonia. Age plays a crucial role, with infants, children under two, and individuals over 65 at increased risk due to their...
1.4K
Atypical Pneumonia01:14

Atypical Pneumonia

Atypical pneumonia, often caused by Mycoplasma pneumoniae, is a form of pulmonary infection that differs from the classical presentation of bacterial pneumonia in both its cause and clinical symptoms. Mycoplasma pneumoniae is a pleomorphic bacterium notable for its lack of a rigid cell wall. This structural characteristic imparts resistance to beta-lactam antibiotics and significantly influences the bacterium’s behavior within the human host.Other pathogens responsible for the disease...
78
Pneumonia II: Pathophysiology01:29

Pneumonia II: Pathophysiology

The pathophysiology of pneumonia involves the following steps:
4.5K
Pneumonia III: Complications and Assessment01:30

Pneumonia III: Complications and Assessment

Pneumonia poses the potential for numerous complications that warrant consideration. These complications include the following:
1.3K
Pulmonary Embolism III: Nursing Management01:27

Pulmonary Embolism III: Nursing Management

A pulmonary embolism occurs when a thrombus, amniotic fluid, tumor tissue, fat, or air embolus blocks one or more pulmonary arteries. Effective nursing management and patient education are crucial for improving outcomes and preventing recurrence.Nursing management starts with obtaining a comprehensive patient history, particularly noting any history of deep vein thrombosis (DVT). Assess for clinical manifestations, including dyspnea, chest pain, crackles, heart murmurs, and signs of right-sided...
746